5TH ANNUAL RALLY WILL BE HELD SEPT 22TH, 2012
5th ANNUAL RALLY FOR ALI
IN SEARCH OF A CURE FOR DIABETES
ALL DONATIONS WILL GO TO HARVARD STEM CELL INSTITUTE
PICNIC FOR A CAUSE
KRAUSE’S GROVE, 2 Beach Road, Halfmoon, NY
SATURDAY, SEPTEMBER 21, 2013
1:00 PM TO 6:00 PM ~ RAIN OR SHINE
$30.00 per adult ticket at gate - $20.00 for children under 12
includes donation to Harvard Stem Cell Institute.
5 hour picnic with soda, beer, games, raffles, 50/50, live music
JAMBONE - THE BEAR BONES PROJECT - BLUE HAND LUKE
SPECIAL GUEST APPEARANCE BY AWARD-WINNING IRISH STEP DANCER
GRACE CATHERINE MOMROW (Ali’s cousin)
Abundant food and dessert being served 1:00 p.m. to 5:00 p.m.
Those who wish to join a pre-picnic motorcycle cavalcade around the beautiful Tomhannock Reservoir in Ali’s honor will meet at the Troy Plaza on Hoosick Street at 10:00 A.M. for sign up and the cavalcade will kick off at 11:00 A.M. sharp.
For more info: https://www.facebook.com/Rally4Ali
For Further Information
For the Run, Wally Urzan
For the Picnic & Cause
Monday, October 11, 2010
FIRST STEM CELL TREATMENT ON A SPINAL CORD PATIENT
(CBS/AP) A California bio-tech company has begun testing an embryonic stem-cell drug treatment on a patient with spinal cord injuries, marking the first time a drug made with embryonic stem cells has been used on a human.
The patient was enrolled at Shepherd Center, a spinal cord and brain injury rehabilitation center in Atlanta.
In order to participate, the patient had to have been injured within the last two weeks. The company, Geron, hopes to enroll another eight to 10 patients in the study.
The stem-cell drug, known as GRNOPC, contains cells that turn into oligodendrocytes, a type of cell that produces myelin, a coating that allows impulses to move along nerves.
When those cells are lost because of injury, paralysis can follow. If GRNOPC1 works, the progenitor cells will produce new oligodendrocytes in the injured area of the patient's spine, potentially allowing for new movement.
Because this is an early stage study, researchers are primarily concerned with the safety of the treatment.
"When we started working with human embryonic stem cells in 1999, many predicted that it would be a number of decades before a cell therapy would be approved for human clinical trials," Dr. Thomas B. Okarma, president and chief executive officer of Geron said in a statement.
Embryonic stem cells have been at the center of funding controversies because the research involves destroying human embryos, which some have argued is akin to abortion.
But, many researchers consider embryonic stem cells the most versatile types of stem cells, as they can morph into any type of cell.
While a milestone in the technology, the drug is still a long way from being proven and reaching the market. It still faces many years of testing for effectiveness if all goes well in the early stage study.